Transplantation of autologous bone marrow-derived mononuclear cells into cerebrospinal fluid in a canine model of spinal cord injury.
Bone marrow–derived mononuclear cells
Canine model
Growth-associated protein 43
Magnetic resonance imaging
Spinal cord injury
Journal
Regenerative therapy
ISSN: 2352-3204
Titre abrégé: Regen Ther
Pays: Netherlands
ID NLM: 101709085
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
18
05
2023
revised:
03
10
2023
accepted:
26
10
2023
medline:
29
11
2023
pubmed:
29
11
2023
entrez:
29
11
2023
Statut:
epublish
Résumé
Spinal cord injury (SCI) is associated with severe dysfunction of nervous tissue, and repair via the transplantation of bone marrow-derived mononuclear cells (BM-MNCs) into cerebrospinal fluid yields promising results. It is essential to understand the underlying mechanisms; therefore, this study aimed to evaluate the regenerative potential of autologous BM-MNC transplantation in a canine model of acute SCI. Six dogs were included in this study, and SCI was induced using an epidural balloon catheter between L2 and L3, particularly in the area of the anterior longitudinal ligament. BM-MNC transplantation was performed, and T2-weighted magnetic resonance imaging (MRI) was conducted at specific time points (i.e., immediately after inducing SCI and at 1, 2, and 4 weeks after inducing SCI); moreover, the expression of growth-associated protein 43 (GAP-43) was evaluated. MRI revealed that the signal intensity reduced over time in both BM-MNC-treated and control groups. However, the BM-MNC-treated group exhibited a significantly faster reduction than the control group during the early stages of SCI induction (BM-MNC-treated group: 4.82 ± 0.135 cm [day 0], 1.71 ± 0.134 cm [1 week], 1.37 ± 0.036 cm [2 weeks], 1.21 cm [4 weeks]; control group: 4.96 ± 0.211 cm [day 0], 2.49 ± 0.570 cm [1 week], 1.56 ± 0.045 cm [2 weeks], 1.32 cm [4 weeks]). During the early stages of treatment, GAP-43 was significantly expressed at the proximal end of the injured spinal cord in the BM-MSC-treated group, whereas it was scarcely expressed in the control group. In SCI, transplanted BM-MNCs can activate the expression of GAP-43, which is involved in axonal elongation (an important process in spinal cord regeneration). Thus, cell therapy with BM-MNCs can provide favorable outcomes in terms of better regenerative capabilities compared with other therapies.
Identifiants
pubmed: 38028937
doi: 10.1016/j.reth.2023.10.003
pii: S2352-3204(23)00102-5
pmc: PMC10654139
doi:
Types de publication
Journal Article
Langues
eng
Pagination
574-581Informations de copyright
© 2023 The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V.
Déclaration de conflit d'intérêts
None.
Références
J Neurosci Res. 2005 Apr 15;80(2):182-90
pubmed: 15772979
Stem Cells. 2014 Apr;32(4):829-43
pubmed: 24155224
Int J Health Sci (Qassim). 2020 Mar-Apr;14(2):24-32
pubmed: 32206057
Cell Regen. 2020 Jun 2;9(1):3
pubmed: 32588151
Cell Biochem Funct. 2017 Aug;35(6):334-338
pubmed: 28845525
Exp Neurol. 2011 May;229(1):174-80
pubmed: 20832402
Mol Ther Methods Clin Dev. 2020 Mar 30;17:657-665
pubmed: 32322604
Circ Res. 2004 Aug 20;95(4):354-63
pubmed: 15321945
Science. 1999 Aug 6;285(5429):886-91
pubmed: 10436156
Vet Surg. 1998 Mar-Apr;27(2):105-11
pubmed: 9525024
Int Rev Cytol. 2005;245:245-325
pubmed: 16125549
Open Vet J. 2020 Aug;10(2):206-215
pubmed: 32821665
Front Neural Circuits. 2013 Feb 21;7:25
pubmed: 23441024
Res Vet Sci. 2016 Aug;107:88-94
pubmed: 27473980
Paraplegia. 1995 Apr;33(4):183-8
pubmed: 7609973
Neural Regen Res. 2022 May;17(5):1034-1041
pubmed: 34558530
Int J Mol Sci. 2019 Apr 12;20(8):
pubmed: 31013780
J Clin Endocrinol Metab. 1999 Aug;84(8):2834-9
pubmed: 10443688
Exp Clin Transplant. 2015 Feb;13(1):100-5
pubmed: 25019162
J Neurosurg Spine. 2016 May;24(5):792-6
pubmed: 26745351
Oncotarget. 2016 Nov 22;7(47):77902-77915
pubmed: 27788490
Glia. 2002 Sep;39(3):229-36
pubmed: 12203389
Int J Immunopathol Pharmacol. 2015 Sep;28(3):351-61
pubmed: 26197804
Nature. 2004 Nov 18;432(7015):324-31
pubmed: 15549094
Exp Clin Transplant. 2012 Jun;10(3):263-72
pubmed: 22631064
Front Immunol. 2019 Jul 16;10:1618
pubmed: 31379825
J Neurotrauma. 2007 Jun;24(6):1026-36
pubmed: 17600518
Stem Cells. 2019 Jan;37(1):6-13
pubmed: 30371964
Vet World. 2021 Apr;14(4):1028-1037
pubmed: 34083956
BMC Genomics. 2009 Feb 24;10:90
pubmed: 19239705
Can J Neurol Sci. 2013 Jul;40(4):456-64
pubmed: 23786727
J Neurosci Methods. 2008 Jan 30;167(2):310-6
pubmed: 17870181
Curr Opin Organ Transplant. 2013 Dec;18(6):682-9
pubmed: 24220051
Stem Cells. 2006 Mar;24(3):686-95
pubmed: 16150920
Cell Cycle. 2020 Feb;19(3):326-338
pubmed: 31944167
Eur Spine J. 2021 Oct;30(10):3107-3114
pubmed: 34283304
Eur Cell Mater. 2018 Mar 6;35:165-177
pubmed: 29509226
Biochem Biophys Res Commun. 2009 Feb 20;379(4):1084-90
pubmed: 19146824
J Neurocytol. 1993 Jan;22(1):51-64
pubmed: 8426193
Biomedicines. 2014 Oct 31;2(4):275-300
pubmed: 28548072
Adv Biomed Res. 2018 Mar 27;7:51
pubmed: 29657936
Nat Med. 1999 Dec;5(12):1410-2
pubmed: 10581084
Curr Neuropharmacol. 2006 Oct;4(4):293-304
pubmed: 18654638
Spine (Phila Pa 1976). 2009 Nov 15;34(24):2605-12
pubmed: 19881401
Int J Neurosci. 2012 Dec;122(12):723-33
pubmed: 22862301
Front Endocrinol (Lausanne). 2018 Aug 30;9:503
pubmed: 30214428